Probi AB, Lund, Sweden.
Department of Clinical Sciences, Lund University, Lund, Sweden.
J Nutr. 2021 Jan 4;151(1):214-222. doi: 10.1093/jn/nxaa353.
Viral infections of the upper airways are the most common cause for absence from work or school, and there is evidence for probiotic efficacy in reducing the incidence and severity of these infections.
We aimed to confirm the previously reported beneficial effects of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 against community-acquired common colds and identify a possible mechanism of action.
In a double-blind study, healthy adults (18-70 years of age) with at least 4 colds during the last 12 months before recruitment were randomly allocated to consume either probiotics (n = 448; total daily dose of 109 CFU with the 2 strains equally represented) or placebo (n = 450) once daily for 12 weeks. Recruitment took place from October to February during 2013-2016 (over 3 cold seasons). The probiotic impact on the severity of the colds (Wisconsin Upper Respiratory Symptom Survey-21) was the primary endpoint, whereas secondary endpoints included the incidence rate and duration of colds and an analysis of immune markers. Mann-Whitney U test and mixed model were used for the analysis of continuous variables and Fisher´s exact test was used for the analysis of categorical endpoints.
Symptom severity was not reduced after intake of the probiotic, despite the positive trend seen in the first season. However, significantly fewer colds were experienced in the probiotic group (mean of 1.24 colds) as compared to the placebo group (mean of 1.36 colds; P = 0.044) for subjects reporting at least 1 cold, the incidence of recurring colds was 30% lower (20.8% vs. 29.8%, respectively; P = 0.055), and the use of analgesics was 18% lower (26.3% vs. 32%, respectively; P = 0.07). After 12 weeks, the change from baseline for IFN-γ differed between the groups (mean difference of -7.01; 95% CI, -14.9 to 0.93; P = 0.045).
Intake of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 can be protective against multiple colds in adults prone to getting colds.This trial was registered at clinicaltrials.gov as NCT02013934.
上呼吸道病毒感染是导致缺勤或缺课的最常见原因，有证据表明益生菌可有效降低这些感染的发生率和严重程度。
我们旨在证实植物乳杆菌 HEAL9 和副干酪乳杆菌 8700:2 先前报道的预防普通感冒的有益作用，并确定其可能的作用机制。
在一项双盲研究中，18-70 岁、在招募前的过去 12 个月中至少患过 4 次感冒的健康成年人被随机分配至服用益生菌（n=448；两种菌株各占一半，每日总剂量为 109 CFU）或安慰剂（n=450），每日 1 次，持续 12 周。招募于 2013-2016 年（3 个感冒季节期间）10 月至 2 月进行。感冒严重程度（威斯康星州上呼吸道症状调查-21）是主要终点，次要终点包括感冒的发生率和持续时间以及免疫标志物分析。使用 Mann-Whitney U 检验和混合模型分析连续变量，使用 Fisher 确切检验分析分类终点。
尽管在第一个季节观察到积极趋势，但服用益生菌后症状严重程度并未降低。然而，与安慰剂组（平均 1.36 次感冒）相比，报告至少 1 次感冒的益生菌组（平均 1.24 次感冒）发生的感冒次数明显更少（P=0.044），复发性感冒的发生率降低了 30%（分别为 20.8%和 29.8%；P=0.055），镇痛药的使用减少了 18%（分别为 26.3%和 32%；P=0.07）。12 周后，两组间 IFN-γ 的基线变化不同（平均差值为-7.01；95%CI，-14.9 至 0.93；P=0.045）。
摄入植物乳杆菌 HEAL9 和副干酪乳杆菌 8700:2 可预防易患感冒的成年人的多次感冒。本试验在 clinicaltrials.gov 上注册为 NCT02013934。
